Navigation Links
Loss Of Dystrophin: Common Thread In Cancer And MS Muscle Wasting

Recent research conducted at the Ohio State University shows that a wasting condition responsible for nearly a third of cancer deaths involves the loss of an essential muscle protein that is also lost in people with muscular // dystrophy.

The study findings, which appear in the November issue of the journal Cancer Cell, show that muscle cells lose significant amounts of the protein dystrophin during cancer wasting, and that subtle changes occur in two other proteins associated with dystrophin in the membrane of muscle cells. These proteins form the dystrophin glycoprotein complex. Dystrophin and DGC are also lost in Duchenne muscular dystrophy.

The loss of dystrophin and damage to the DGC appear to be key players in the development of both cancer wasting and muscular dystrophy.

Cancer wasting occurs most often in esophageal, stomach, colorectal, pancreatic, lung, and head and neck cancers. Cancer patients who develop wasting usually respond more poorly to therapy and have a shorter life span and lower quality of life.

The findings provide a better understanding of cancer wasting, also known as cancer cachexia, a condition first described more than 100 years ago that still lacks effective therapy. The findings also might lead to new ways to diagnose and treat the condition.

Cancer wasting occurs most often in esophageal, stomach, colorectal, pancreatic, lung, and head and neck cancers. The condition is induced by growth of the tumor, and it results in the loss of both fat and skeletal muscle mass. Cancer patients who develop wasting usually respond more poorly to therapy and have a shorter life span and lower quality of life.

Muscular dystrophy is a genetic disease that usually begins in childhood and results in the complete loss of dystrophin and the DGC from muscle.

The researchers found that dystrophin levels were reduced in the muscles of mice with cancer cachexia, and that two DGC pr oteins were altered. The researchers then showed that cachexia is accelerated in mice that lack dystrophin and develop cancer. Furthermore, they showed that they could prevent cancer wasting in the mice by causing their muscle cells to over-produce dystrophin.

Last, the researchers tested muscle biopsies from 27 patients with gastrointestinal cancers for dystrophin and DGC. Eleven of the patients were confirmed cachectic, and ten of those showed dramatic reductions in dystrophin and significant loss of the DGC.

The authors conclude that the evidence strongly suggests that the wasting conditions in cancer and muscular dystrophy patients are similar, and that the loss of dystrophin and the DGC are important contributing factors in tumor-induced muscle wasting.
'"/>




Related medicine news :

1. Common contraception
2. Common Cold Remedy May Treat SARS
3. Common Plant Triggers Asthma
4. Pain Common in People with MS
5. Common Cold Found to Fight Cancer
6. Bullying – a Common Problem Among Childre
7. Common Medication Errors in Children
8. A Common Cause Of Allergy That Goes Unnoticed
9. Genetic Breakthrough in Common Eye Problem
10. Common Cold Found to Fight Cancer Cells
11. Side Effects Of Some Common Drugs
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
(Date:6/23/2016)... NORTHBROOK, Ill. and BOGOTA, Colombia , June 23, 2016  Astellas today announced the ... joins Astellas Farma Brasil as the company,s second affiliate in Latin America . ... ... appointed General Manager of Astellas Farma Colombia ... ...
(Date:6/23/2016)... Research and Markets has announced ... Analysis (United States, China, Japan, Brazil, United Kingdom, Germany, ... offering. Surgical Procedure ... planners, provides surgical procedure volume data in a geographic ... in-depth analysis of growth drivers and inhibitors, including world ...
Breaking Medicine Technology: